[Asthenic disorders in children and their differentiated treatment].
OBJECTIVE
To study clinical/psychological characteristics of neurasthenia and residual asthenia and to assess the efficacy of noofen and adaptol in the treatment of these disorders.


METHODS
Authors examined 30 adolescents with neurasthenia and 30 with residual asthenia. The Multidimensional Fatigue Inventory (MFI-20), A.M. Vein questionnaire, Spilberger-Khanin questionnaire, The Test of Variables of Attention (TOVA) were used. Patients were divided into two equal groups (n=30), each included 15 patients with residual asthenia and neurasthenia. Patients of the first group received adaptol in dosage 1000 mg daily and patients of the second group received noofen in dosage 500 mg daily. The duration of the study was 30 days.


CONCLUSIONS
The significantly higher levels of fatigue, inattention and exhaustibility were identified in patients with residual asthenia. Adolescents with neurasthenia were characterized by higher anxiety. The higher efficacy of adaptol in treatment of neurasthenia (80% in adolescents with neurasthenia and 60% of patients with residual asthenia) was shown. Noofen was more effective in treatment of residual asthenia (66.7% of adolescents with neurasthenia and 86.7% with residual asthenia.
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
L S
LS
Chutko
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
S Iu
SI
Surushkina
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
I S
IS
Nikishena
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
E A
EA
Iakovenko
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
T I
TI
Anisimova
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
Iu L
IL
Bondarchuk
FGBU 'Institut mozga cheloveka im. N.P. Bekhterevoĭ' RAN, Sankt-Peterburg.
A V
AV
Sergeev
D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000175:diagnosis / Q000188:drug therapy; D001247:Asthenia / Q000175:diagnosis* / Q000188:drug therapy*; D001736:Biureas / Q000627:therapeutic use*; D005221:Fatigue / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D018755:GABA Agonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009440:Neurasthenia / Q000175:diagnosis* / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D012647:Self-Assessment; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D001736:Biureas; D018755:GABA Agonists; C015979:mebikar; D005680:gamma-Aminobutyric Acid; C008842:4-amino-3-phenylbutyric acid